I serve as Vice President and Franchise Head in Late Oncology R&D at AstraZeneca. In my current role, I lead the cross-functional R&D特许开发和推出两种关键的晚期肿瘤分子:capivasertib和AZD9833.  As part of that I also lead the Global Product Team for capivasertib.

Having spent more than 30 years in a pharmaceutical research setting, 我在药物开发方面的经验涵盖了心血管和肿瘤治疗领域，涵盖了药物开发的各个阶段.  在肿瘤学方面，我曾参与研究包括乳腺癌在内的一系列肿瘤类型的项目, prostate, lung, gastrointestinal, acute myeloid leukaemia and diffuse large B-cell lymphoma. 

我于2003年加入澳门在线赌城娱乐临床运营部，此后在临床运营和战略药物开发方面担任职务，职责不断提升，包括开发和交付广泛的国际药物开发项目.  在这些职位上，我发现了与外部专家合作的巨大价值，在我的职业生涯中也是如此, 我曾组织和主持企业和学术顾问委员会，并担任多个学术指导委员会的秘书.

Before joining AstraZeneca, I was an Executive Director and Board Member at NCRL, 这是一家专业的合同研究机构，专门从事大型心血管研究的设计和交付，我在从一家大学分拆出来的公司发展企业方面发挥了主导作用.

与外部研究界保持联系对我来说非常重要，我在澳门在线赌城娱乐之外担任许多荣誉职位，包括英国制药工业协会新药和数据战略领导小组主席, co-chair of the UK Clinical Pharmacology Skills Alliance, 英国临床药理学先驱学徒小组主席.  

 

At AstraZeneca, 澳门第一赌城在线娱乐致力于推动肿瘤研究的新边界，并帮助加快高质量的交付, targeted medicines to patients. 我热衷于将科学研究转化为改善患者生活的成果.

Andrew Foxley Vice President, Franchise Head, Late Oncology R&D

CURRENT ROLE

Vice President, R&D Franchise Head, Late Oncology R&D

2019 – 2020

作为项目副总裁，领导跨职能的全球产品团队进行capivasertib的后期开发, Global Medicines Leader at AstraZeneca

2017 – 2019

曾担任澳门在线赌城娱乐(AstraZeneca)后期开发的全球过渡总监，以支持分子准备从早期开发转向后期开发-这包括将capivasertib引入后期开发

2015 – 2017

曾担任澳门在线赌城娱乐早期肿瘤转化医学部门的临床项目管理主管

Featured publications

Capivasertib +紫杉醇与安慰剂+紫杉醇作为转移性三阴性乳腺癌的一线治疗:PAKT试验.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. J Clin Oncol. 2020 Feb 10;38(5):423-433

http://pubmed.ncbi.nlm.nih.gov/31841354/

 

氟维司汀加capivasertib与安慰剂在芳香酶抑制剂复发或进展后转移, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Lancet Oncol. 2020 Mar;21(3):345-357

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30817-4/fulltext

 

Capivasertib (AZD5363)治疗ER+侵袭性乳腺癌(STAKT)后细胞增殖及AKT活性生物标志物分析.

Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Clin Cancer Res. 2020 Apr 1;26(7):1574-1585

http://pubmed.ncbi.nlm.nih.gov/31836609/

 

Capivasertib, an AKT Kinase Inhibitor, AKT1 e17k突变体患者单药治疗或与富维司汀联合治疗, ER-Positive Metastatic Breast Cancer.

Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Pass M, Rowlands V, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Clin Cancer Res. 2020 Apr 20:clincanres.3953

http://pubmed.ncbi.nlm.nih.gov/32312891/

 

一项I期开放标签研究确定泛akt抑制剂AZD5363在实体瘤和pik3ca突变的乳腺癌和妇科癌症中的给药方案.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. Clin Cancer Res. 2018 May 1;24(9):2050-2059

http://pubmed.ncbi.nlm.nih.gov/29066505/

 

A Phase 1, open-label, 多中心研究比较AZD5363胶囊和片剂制剂，探讨食物对其药代动力学暴露的影响, AZD5363在晚期实体恶性肿瘤患者中的安全性和耐受性.

Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, Bailey C, Casson E, Cripps D, Cullberg M, Evans S, Foxley A, Lindemann J, Rugman P, Taylor N, Turner G, Yates J, Lawrence P. Cancer Chemother Pharmacol. 2018 May;81(5):873-883

http://pubmed.ncbi.nlm.nih.gov/29541803/

 

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. J Clin Oncol. 2017 Jul 10;35(20):2251-2259

http://pubmed.ncbi.nlm.nih.gov/28489509/